Key Points
- Jason Adair sold 35,656 shares of Liquidia on November 18 at an average price of $30.03 for roughly $1.07 million, reducing his ownership by 16.93% to 174,998 shares, per an SEC filing.
- Liquidia reported a quarterly EPS of ($0.04), beating estimates of ($0.45), and revenue of $54.34 million versus $18.86 million expected, a year-over-year increase of about 1,106.7%.
- Analysts have a consensus rating of “Moderate Buy” with an average price target of $38.56; the stock has a market cap around $2.47 billion and a 1‑year range of $10.02–$30.88.
Liquidia Corporation (NASDAQ:LQDA - Get Free Report) insider Jason Adair sold 35,656 shares of the company's stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $30.03, for a total value of $1,070,749.68. Following the sale, the insider directly owned 174,998 shares of the company's stock, valued at approximately $5,255,189.94. This represents a 16.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Jason Adair also recently made the following trade(s):
- On Monday, October 27th, Jason Adair sold 692 shares of Liquidia stock. The shares were sold at an average price of $22.93, for a total value of $15,867.56.
- On Monday, October 13th, Jason Adair sold 3,670 shares of Liquidia stock. The stock was sold at an average price of $23.41, for a total transaction of $85,914.70.
- On Tuesday, September 2nd, Jason Adair sold 451 shares of Liquidia stock. The stock was sold at an average price of $29.05, for a total transaction of $13,101.55.
- On Tuesday, September 2nd, Jason Adair sold 451 shares of Liquidia stock. The shares were sold at an average price of $29.05, for a total value of $13,101.55.
- On Thursday, August 28th, Jason Adair sold 26,057 shares of Liquidia stock. The shares were sold at an average price of $27.86, for a total value of $725,948.02.
Liquidia Trading Down 0.7%
Shares of LQDA stock opened at $28.37 on Friday. The company has a current ratio of 2.20, a quick ratio of 1.96 and a debt-to-equity ratio of 6.19. Liquidia Corporation has a 1 year low of $10.02 and a 1 year high of $30.88. The firm's fifty day simple moving average is $24.53 and its 200 day simple moving average is $20.69. The firm has a market capitalization of $2.47 billion, a P/E ratio of -19.70 and a beta of 0.12.
Liquidia (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings data on Monday, November 3rd. The company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.41. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The company had revenue of $54.34 million during the quarter, compared to the consensus estimate of $18.86 million. Liquidia's revenue was up 1106.7% compared to the same quarter last year. As a group, sell-side analysts predict that Liquidia Corporation will post -1.51 EPS for the current year.
Institutional Trading of Liquidia
Several hedge funds have recently modified their holdings of the stock. Skandinaviska Enskilda Banken AB publ bought a new position in shares of Liquidia during the 3rd quarter worth approximately $30,000. NewEdge Advisors LLC purchased a new stake in shares of Liquidia during the second quarter valued at approximately $25,000. Hurley Capital LLC purchased a new position in Liquidia during the 1st quarter valued at about $32,000. Quarry LP bought a new position in Liquidia in the first quarter worth about $79,000. Finally, Steward Partners Investment Advisory LLC increased its stake in shares of Liquidia by 24.0% during the second quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company's stock valued at $77,000 after purchasing an additional 1,200 shares in the last quarter. Institutional investors own 64.54% of the company's stock.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on LQDA shares. Wells Fargo & Company initiated coverage on shares of Liquidia in a research note on Monday, October 20th. They issued an "overweight" rating and a $31.00 price objective on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Liquidia in a report on Wednesday, October 8th. Raymond James Financial reaffirmed a "strong-buy" rating and issued a $47.00 target price on shares of Liquidia in a report on Tuesday, November 4th. Jefferies Financial Group reiterated a "buy" rating and issued a $45.00 price objective on shares of Liquidia in a report on Monday, November 3rd. Finally, HC Wainwright upped their target price on Liquidia from $35.00 to $50.00 and gave the company a "buy" rating in a research report on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, Liquidia has a consensus rating of "Moderate Buy" and an average price target of $38.56.
Check Out Our Latest Stock Report on Liquidia
About Liquidia
(
Get Free Report)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
